Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
EnviroGold Closes Upsized Unit Offering Raising $4.1M and Announces New Director (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GeoVax Labs Inc GOVX

Healthcare Biotechnology
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include... see more

Recent & Breaking News (NDAQ:GOVX)

GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial

TheNewsWire 1 day ago

GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024

TheNewsWire 3 days ago

GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025

TheNewsWire 8 days ago

GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025

TheNewsWire 10 days ago

GeoVax Receives Notice of Allowance For Cancer Vaccine Patent

GlobeNewswire December 9, 2024

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference

GlobeNewswire November 26, 2024

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GlobeNewswire November 19, 2024

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire November 12, 2024

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

GlobeNewswire November 5, 2024

GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GlobeNewswire October 2, 2024

GeoVax to Participate in Upcoming Investor Conferences in September

GlobeNewswire September 3, 2024

GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

GlobeNewswire August 28, 2024

Registration is Now Open for Tribe Public's Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab's CEO

GlobeNewswire August 21, 2024

GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market

GlobeNewswire August 20, 2024

GeoVax to Present at the Emerging Growth Conference on August 21, 2024

GlobeNewswire August 15, 2024

GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

GlobeNewswire August 8, 2024

GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire August 6, 2024

Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review

GlobeNewswire July 31, 2024

GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review

GlobeNewswire July 31, 2024

GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024

GlobeNewswire July 30, 2024